The confirmatory randomized Phase III MIRASOL trial further validated the clinical utility of mirvetuximab in the population of platinum-resistant, advanced high-grade epithelial ovarian, peritoneal, or fallopian tube cancers, with FRα-high expression (≥75% of tumor cells with 2+/3+ staining) [13]. Here, FOLR1 is linked to neoplasm.